Next Article in Journal
Involvement of Astrocytes in Mediating the Central Effects of Ghrelin
Next Article in Special Issue
Proline Residues as Switches in Conformational Changes Leading to Amyloid Fibril Formation
Previous Article in Journal
Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions
Previous Article in Special Issue
Recent Progress in Machine Learning-Based Methods for Protein Fold Recognition
Article

High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors

1
Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, 08193 Bellaterra, Spain
2
Department of Biochemistry and Molecular and Cell Biology, Institute for Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, 50018 Zaragoza, Spain
3
Institute of Biotechnology and Biomedicine, Autonomous University of Barcelona, 08193 Bellaterra, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Irmgard Tegeder
Int. J. Mol. Sci. 2017, 18(3), 478; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18030478
Received: 15 December 2016 / Revised: 15 January 2017 / Accepted: 20 January 2017 / Published: 2 March 2017
(This article belongs to the Collection Protein Folding)
An increasing number of neurodegenerative diseases are being found to be associated with the abnormal accumulation of aggregated proteins in the brain. In Parkinson’s disease, this process involves the aggregation of alpha-synuclein (α-syn) into intraneuronal inclusions. Thus, compounds that inhibit α-syn aggregation represent a promising therapeutic strategy as disease-modifying agents for neurodegeneration. The formation of α-syn amyloid aggregates can be reproduced in vitro by incubation of the recombinant protein. However, the in vitro aggregation of α-syn is exceedingly slow and highly irreproducible, therefore precluding fast high throughput anti-aggregation drug screening. Here, we present a simple and easy-to-implement in-plate method for screening large chemical libraries in the search for α-syn aggregation modulators. It allows us to monitor aggregation kinetics with high reproducibility, while being faster and requiring lower protein amounts than conventional aggregation assays. We illustrate how the approach enables the identification of strong aggregation inhibitors in a library of more than 14,000 compounds. View Full-Text
Keywords: high-throughput screening; α-synuclein; Parkinson disease; amyloid; protein aggregation high-throughput screening; α-synuclein; Parkinson disease; amyloid; protein aggregation
Show Figures

Figure 1

MDPI and ACS Style

Pujols, J.; Peña-Díaz, S.; Conde-Giménez, M.; Pinheiro, F.; Navarro, S.; Sancho, J.; Ventura, S. High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors. Int. J. Mol. Sci. 2017, 18, 478. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18030478

AMA Style

Pujols J, Peña-Díaz S, Conde-Giménez M, Pinheiro F, Navarro S, Sancho J, Ventura S. High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors. International Journal of Molecular Sciences. 2017; 18(3):478. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18030478

Chicago/Turabian Style

Pujols, Jordi, Samuel Peña-Díaz, María Conde-Giménez, Francisca Pinheiro, Susanna Navarro, Javier Sancho, and Salvador Ventura. 2017. "High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors" International Journal of Molecular Sciences 18, no. 3: 478. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18030478

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop